Sensus Healthcare (SRTS) AI Stock Analysis

• Market Cap: $84.36M
• Dividend Yield: N/A
• Average Volume (3M): 89.19K
• Price to Earnings (P/E): 46.4
• Beta (1Y): 1.08
• Revenue Growth: 24.75%
• EPS Growth: -61.29%
• Country: US
• Employees: 54
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 16,445,036
• 10 Day Avg. Volume: 61,357
• 30 Day Avg. Volume: 89,192
• PEG Ratio: 0.01
• Price to Book (P/B): 2.54
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -77.84
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 0.62
• Enterprise Value/Gross Profit: 4.42
• Enterprise Value/Ebitda: 2.95
• 1Y Price Target: $11.25
• Price Target Upside: 120.59% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 65 Neutral
• Price Target: $5.00 ▼(-1.96%Downside)

Sensus Healthcare shows strong financial performance with robust revenue and profit growth, supported by a solid balance sheet. However, concerns include negative cash flow and high valuation metrics. The technical analysis is neutral, while the earnings call provides a mixed outlook with potential future growth. These factors combined result in a moderate stock score.

Positive Factors

Device Shipments

The company achieved a quarterly record by shipping 39 SRT systems in 4Q24 and exceeded expectations by shipping 115 systems for FY2024.

Program Expansion

Sensus Healthcare expanded its Fair Deal Agreement programs, which could generate recurring revenue and contribute to growth.

Revenue Growth

Sensus Healthcare reported a 71% year-over-year revenue growth for FY2024, beating projections and supporting a Buy rating.

Negative Factors

Competition

SkinCure announced it would be exhibiting a fourth-generation SRT device that would compete with Sensus SRT-100 Vision image-guided SRT offering.

Investment Risks

Investment risks include potential failure of SRT systems to achieve commercial success due to reimbursement, penetration rate, and competition.

Revenue Estimates

Despite positive momentum, the company is lowering its revenue estimates and 12-month price target due to a slower expected revenue ramp with the inclusion of the Fair Deal Agreement model.

Sensus Healthcare Business Overview & Revenue Model

Company Description

Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and in-office laser rental services. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.

How the Company Makes Money

Sensus Healthcare generates revenue primarily through the sale and leasing of its SRT-100 devices to dermatology clinics, hospitals, and healthcare facilities. The company also earns income from service contracts and maintenance agreements, providing ongoing support and ensuring optimal performance of their devices. Additionally, Sensus may engage in partnerships or collaborations with other healthcare providers to expand its market reach and drive sales growth. Revenue is further supplemented by training and support services offered to healthcare professionals using their technology.

Sensus Healthcare Financial Statement Overview

Summary

Sensus Healthcare demonstrated strong revenue and profit growth with improved gross profit and net profit margins. The balance sheet is robust with low leverage and high equity ratio, indicating financial stability. However, the negative free cash flow highlights a need for better cash management.

Income Statement

Sensus Healthcare showed remarkable revenue growth of 71.3% from the previous year. The gross profit margin improved significantly to 58.4%, reflecting increased operational efficiency. Net profit margin also improved substantially to 15.9%, indicating enhanced profitability. However, the EBIT margin of 19.3% and EBITDA margin of 19.3% suggest room for improvement in controlling operating expenses.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 89.8%, demonstrating financial stability. The debt-to-equity ratio is low at 0.01, indicating minimal leverage and reduced financial risk. Return on equity improved significantly to 11.9%, showcasing effective utilization of shareholder funds. Overall, the balance sheet reflects solid financial health.

Cash Flow

Sensus Healthcare's free cash flow improved but remains negative, indicating potential challenges in cash management. The operating cash flow to net income ratio is negative, suggesting a need to enhance cash generation from operations. Despite these challenges, the free cash flow deficit has narrowed, showing some progress towards achieving positive cash flows.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
39.49M	41.81M	24.41M	44.53M	27.04M	9.58M
	Gross Profit
22.12M	24.43M	14.06M	29.63M	16.99M	5.25M
	EBIT
2.56M	8.09M	-382.00K	14.83M	4.12M	-8.23M
	EBITDA
2.79M	8.52M	79.00K	14.83M	4.73M	-6.10M
	Net Income Common Stockholders
1.80M	6.65M	485.00K	24.24M	4.12M	-4.72M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.07M	22.06M	23.15M	25.52M	14.52M	14.91M
	Total Assets
60.21M	62.16M	53.71M	56.73M	32.24M	28.01M
	Total Debt
654.00K	602.00K	783.00K	1.02M	225.00K	1.38M
	Net Debt
-18.42M	-21.45M	-22.36M	-24.50M	-14.29M	-13.52M
	Total Liabilities
7.18M	6.34M	4.87M	8.67M	6.22M	6.51M
	Stockholders Equity
53.03M	55.83M	48.84M	48.07M	26.02M	21.50M
Cash Flow		Free Cash Flow
4.64M	-1.11M	-2.37M	-1.57M	-414.00K	-792.73K
	Operating Cash Flow
4.68M	-831.00K	-2.15M	-1.41M	-286.00K	-434.18K
	Investing Cash Flow
-50.00K	-276.00K	-187.00K	14.84M	129.00K	7.03M
	Financing Cash Flow
-285.00K	15.00K	-40.00K	-2.43M	-231.00K	210.01K

Sensus Healthcare Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.10
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRTS, the sentiment is Positive. The current price of 5.1 is above the 20-day moving average (MA) of 4.82, above the 50-day MA of 4.66, and below the 200-day MA of 6.04, indicating a neutral trend. The MACD of 0.12 indicates Negative momentum. The RSI at 62.42 is Neutral, neither overbought nor oversold. The STOCH value of 72.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SRTS.

Sensus Healthcare Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	65 Neutral	$84.36M	46.41	3.46%	―	24.75%	-61.29%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
EDAP	45 Neutral	$64.31M	―	-51.63%	―	11.26%	-14.21%
XBIT		$88.72M	―	-20.53%	―	―	―
ADAG	49 Neutral	$92.33M	―	-55.14%	―	-99.43%	-69.40%
CLSD	43 Neutral	$62.94M	―	91.63%	―	-55.47%	24.92%
VOR	33 Underperform	$28.68M	―	-125.43%	―	―	2.98%

Sensus Healthcare Corporate Events

Sensus Healthcare Elects New Director at Annual Meeting

At the Annual Meeting of Stockholders held on May 27, 2025, Sensus Healthcare elected Anthony Petrelli as a Class I director for a three-year term. Stockholders approved an amendment to the 2017 Incentive Plan, extending its term and increasing the share issuance limit. Additionally, the compensation of the company’s executive officers for 2024 was approved on an advisory basis, and Berkowitz Pollack Brant Advisors + CPAs, LLP was ratified as the independent registered public accountant for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SRTS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Sensus Healthcare stock, see the SRTS Stock Forecast page.